AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
May 19, 2021
29864_dirs_2021-05-19_fde66c89-e873-45fd-9434-6cb22561f39a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-05-17
Reporting Person: Sachdev Amit (EVP, Chief Patient Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-17 | Common Stock | S | 8 | $215.59 | Disposed | 40170 | Direct |
| 2021-05-17 | Common Stock | S | 32 | $216.40 | Disposed | 40138 | Direct |
| 2021-05-17 | Common Stock | S | 5 | $217.27 | Disposed | 40133 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 882 | Indirect |
| Common Stock | 7368 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $215.59 (range $214.94 to $215.93).
F3: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $216.40 (range $215.95 to $216.91).
F5: Open market sales reported on this line occurred at a weighted average price of $217.27 (range $217.05 to $217.46).